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As glargine, an analog of human insulin, is increasingly used during pregnancy, a meta-analysis assessed its safety in this
population. A systematic literature search identified studies of gestational or pregestational diabetes comparing use of insulin
glargine with human NPH insulin, with at least 15 women in both arms. Data was extracted for maternal outcomes (weight at
delivery, weight gain, 1st/3rd trimester HbA1c, severe hypoglycemia, gestation/new-onset hypertension, preeclampsia, and cesarean
section) and neonatal outcomes (congenital malformations, gestational age at delivery, birth weight, macrosomia, LGA, 5 minute
Apgar score >7, NICU admissions, respiratory distress syndrome, neonatal hypoglycemia, and hyperbilirubinemia). Relative risk
ratios and weighted mean differences were determined using a random effect model. Eight studies of women using glargine (331)
or NPH (371) were analyzed. No significant differences in the efficacy and safety-related outcomes were found between glargine
and NPH use during pregnancy.
1. Introduction
An estimated 4% of pregnancies in the United States are
complicated by diabetes [1]. Whether due to preexisting type
1 or type 2 diabetes mellitus (pregestational) or diabetes that
developed during pregnancy (gestational), hyperglycemia
during pregnancy is associated with increased risk of various
maternal and fetal complications. Subclinical increases in
fasting blood glucose levels as little as 6.9mg/dL and elevated
postprandial plasma glucose levels have been associated
with a greater risk of developing both maternal and fetal
complications [2]. Women with pregestational diabetes
may experience worsening of retinopathy or nephropathy
[3], and both pregestational and gestational diabetes are
associated with increased risk of hypertension, preeclampsia,
and delivery by cesarean section [4–13]. Fetal complications
include congenital malformations, premature delivery, peri-
natal death, macrosomia and traumatic delivery, neonatal
hypoglycemia or respiratory distress, admission to a neonatal
intensive care unit, and risk of developing obesity or diabetes
later in life [4, 9–25]. Becausemany of these problemsmay be
reduced by improved glycemic control [26], efforts to main-
tain nearly normal levels of glucose are recommended during
pregnancy associated with diabetes, frequently requiring the
use of insulin.
The insulin preparations most widely used in this setting
have been neutral protamine hagedorn (NPH) human
insulin and short-acting human insulin, or insulin analogs.
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American Diabetes Association (ADA) guidelines recom-
mend that patients using basal insulin analogs be transi-
tioned to NPH insulin, preferably prior to pregnancy [27].
Clinical trials have shown that, in comparison to NPH, the
basal insulin glargine can, under appropriate circumstances,
improve glycemic control and reduce the frequency of
hypoglycemia and thus may be beneficial in pregnancies
associated with diabetes [28, 29]. However, the safety of
using insulin glargine during pregnancy has not been fully
demonstrated, and concern about abnormal binding of this
analog to the insulin-like growth factor 1 (IGF-1) receptor
has been voiced [30–32]. For this reason, we performed a
literature search and meta-analysis to examine published
experience with the use of insulin glargine, assessing both
maternal and fetal outcomes.
2. Methods
2.1. Identification of Studies. Studies published by 30 January
2011 were identified by a systematic literature search in
MEDLINE, EMBASE, and the Cochrane Central Register for
Controlled Trials database. The search was executed with
no language restrictions and using pairwise combinations
“insulin glargine” or Lantus with the following terms: preg-
nancy, pregnant, neonatal, fetal, foetal, perinatal, and mater-
nal. Hand searching of the reference lists of the retrieved
articles and relevant reviews was performed. The registry
at http://www.clinicaltrials.gov/ was searched to identify
unpublished clinical trial data regarding insulin glargine use
during pregnancy reported by the cutoff date. Unpublished
studies reported in abstracts from conferences were excluded
from the study. Two investigators independently screened
the title and abstract of each reference identified by the
search and applied the following inclusion criteria with any
differences in opinion resolved by a third party. The inclu-
sion criteria consisted of (1) study type—retrospective or
prospective observational case-control study, cohort study,
or randomized controlled trial; (2) participants—pregnant
women with pregestational and/or gestational diabetes; (3)
interventions—insulin glargine and NPH insulin; (4) study
size—studies with ≥15 women per arm. The full articles
of those studies that satisfied the inclusion criteria were
retrieved and assessed independently with the final eligibility
of studies decided by consensus. The quality of the reporting
of studies to be included in the meta-analysis was assessed
using the Strengthening of the Reporting of Observational
Studies in Epidemiology (STROBE) statement guidelines
[33].
2.2. Data Extraction. Data extraction forms were used to
obtain the data from each study included in the meta-
analysis. Data was extracted for study subjects treated
with either NPH or insulin glargine; study “control” sub-
jects who did not have diabetes or did not receive basal
insulin therapy were not included in the meta-analysis.
The maternal baseline characteristics extracted included:
maternal age, duration of diabetes, prepregnancy weight, and
prepregnancy body mass index (BMI). The maternal out-
comes assessed were weight at delivery, weight gain, 1st
and 3rd trimester HbA1c levels, episodes of severe hypo-
glycemia, gestational/new-onset hypertension, preeclamp-
sia, and cesarean section. Neonatal outcomes were gesta-
tional age at delivery, birth weight, neonatal ICU (NICU)-
admission, 5 minute Apgar score <7, macrosomia (birth
weight >4000 g), large for gestational age (birth weight
>90th percentile for their gestational age, LGA), congeni-
tal malformations, respiratory distress syndrome, neonatal
hypoglycemia, and hyperbilirubinemia.
2.3. Assessment of Heterogeneity. Heterogeneity between tri-
als was assessed by the χ2-test. Quantification of heterogene-
ity was also examined with I2, which measures the degree of
total variation across studies due to heterogeneity and can be
used to judge the consistency of evidence. Higher I2 values
correspond to increasing heterogeneity [34].
2.4. Data Synthesis. In the event that a study stratified its par-
ticipants by pregestational/gestational diabetes status or by
diabetes type prior to analysis, the outcomes for each cohort
were combined to create a single cohort result. For continu-
ous data, the mean and standard deviation of the combined
cohort were calculated from the separate cohort results
using standard formulas. Dichotomous data presented as
percentages were converted to counts and combined. All
meta-analysis outcomes were assessed using a random effects
model which incorporated the impact of heterogeneity in
the analysis. Weighted mean differences (WMDs) with 95%
confidence intervals (CIs) were determined for continuous
data using the inverse variance method. Mantel-Haenszel
odds ratios (OR) with 95% confidence intervals were deter-
mined for dichotomous data. All analyses were performed
using Review Manager (RevMan, version 5.1, Copenhagen:
Cochrane Collaboration). In addition, all forest plots were
generated by RevMan.
3. Results
3.1. Description of Studies. The initial literature search
identified 49 articles; no further relevant studies or clinical
data were retrieved from the searches of the Cochrane
database or the clinical trial registry (Figure 1). Twenty-five
of these articles did not contain human data and were ex-
cluded. An additional thirteen studies were excluded due to
an insufficient number of participants; six articles were case
studies, and seven were reports regarding the outcomes of
four to thirteen subjects. Three studies were excluded due
to the absence of an appropriate basal insulin comparison
group. Eight studies satisfied the inclusion criteria and, after
confirming adherence to STROBE guidelines, were included
in the meta-analysis (Table 1) [35–42]. When combined, the
eight observational cohort studies consisted of a total of
702 women with pregestational and/or gestational diabetes,
of whom 331 received insulin glargine and 371 received
NPH insulin. Five of the studies examined women with
both pregestational and gestational diabetes [36, 37, 39,
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Figure 1: Study flow.
41, 42]. Only two of the five studies specified the type of
pregestational diabetes [41, 42]. The remaining three studies
included only women with pregestational type 1 diabetes
[35, 38, 40].
3.2. Maternal Baseline Characteristics. Baseline maternal
characteristics are reported in Table 2. Information on each
maternal baseline characteristic was reported in three to
seven of the eight studies (Table 2). Overall, there was no
difference in maternal age, body weight, or body mass index
between the women using insulin glargine and those using
NPH insulin, while the duration of diabetes was longer
among insulin glargine users. Although women using insulin
glargine were slightly younger compared to NPH insulin
users, the difference was not statistically significant [35–
39, 41, 42]. Similarly, while the mean prepregnancy weight of
glargine users was 1.53 kg greater that of NPH users [37–39,
41] whose mean prepregnancy BMI was 0.46 kg/m2 greater
than that of glargine users [35, 36, 41], weight and BMI were
comparable between insulin groups in all studies and the
overall mean differences were not statistically significant
(Table 2).
Duration of diabetes was reported in seven studies [35,
36, 38–42]. While duration of diabetes was longer in glargine
users (Table 2), there was considerable variation between
the studies (I2 = 48%). This may be explained by the
combination of women with type 1 and type 2 diabetes
into a single diabetes cohort. Subanalysis of five studies that
reported the duration of type 1 diabetes revealed a more
homogeneous population (I2 = 6%), but glargine users
still had longer duration of diabetes (Table 2, P = 0.0001)
[35, 38, 40, 41]. In contrast, the three studies reporting
the duration of pregestational diabetes without distinction
between type of diabetes had a high degree of variation (I2
= 71%) [36, 39, 42]. When standardized weighted mean
differences were utilized to compensate for the variation in
the duration of diabetes measurements that is inherent to the
type of diabetes (i.e., due to earlier onset, patients with type
1 diabetes are expected to have a longer duration of diabetes
in comparison to patients with type 2 diabetes), the mean
difference between insulin glargine and NPH users was no
longer statistically significant (0.38 years (−0.11 to 0.88)).
Eight studies reported on difference in maternal age
between insulins, but only seven studies reported the mean
maternal age [35–39, 41, 42]. When combined, there was
no significant difference in maternal age between insulin
glargine and NPH users (Table 2). Although six studies in-
dividually reported no difference in maternal age between
glargine and NPH users, in one study, women with type 1
pregestational diabetes that were treated with insulin glargine
were significantly younger than those that were treated with
NPH [41]. This observation may explain some of the hetero-
geneity between the trials (I2 = 57%).
3.3. Maternal Outcomes. The meta-analysis included the
data that was available for each maternal outcome in four
to eight of the identified studies (Table 3). Overall, there was
no significant difference in any maternal outcome between
Glargine and NPH users (Table 3 and Figure 2). Additionally,
third trimester HbA1c [35–37, 39–42], maternal weight [36,
38, 39, 41], and rate of cesarean section at delivery [34–
36, 38, 39, 41] did not differ significantly between insulins
in any individual study.
Weight gain during pregnancy was reported in five
studies [35–39]. Four studies individually reported that
weight gain was comparable between insulins while one
study reported lower weight gain among glargine users (6.7
versus 11.4 kg; P < 0.01) [41]. There was no difference in
weight gain in the meta-analysis. HbA1c levels measured at
any time during the first trimester were reported in four
studies (Figure 2(a)) [35, 36, 38, 40]. Of the three studies
which investigated women with type 1 diabetes, one found
that glargine use was associated with lower 1st trimester
HbA1c levels (6.9 versus 7.8%; P = 0.04) [38]. There was
considerable variation in HbA1c levels between the studies
(I2 = 79%) that could not be explained by the type of
diabetes.
Although six studies reported hypoglycemia data, only
three explicitly defined severe maternal hypoglycemia as an
episode requiring the assistance of another person [35, 39,
40]. A further study was included as it used a classification of
mild and severe hypoglycemia [38]. While there was no over-
all difference in the prevalence of severe hypoglycemia with
glargine or NPH use (Table 3, Figure 2(b)), one study found
that the use of NPH was associated with a higher incidence
of severe hypoglycemia among women with pregestational
diabetes (27% versus 0%; P < 0.0001) [39]. There was
substantial heterogeneity between the studies (I2 = 52%) not
explained by type of diabetes.
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Table 2: Baseline maternal characteristics of pregnant women using insulin glargine versus NPH among the studies selected for meta-
analysis.
Maternal
characteristic
Number of
studies
Insulin glargine NPH Mean
difference∗
95% confidence limits
Unadjusted
mean/events
Number of
Patients
Unadjusted
mean/events
Number of
Patients
Lower
limit
Upper
limit
Maternal age (yrs) 7 30.3 289 30.5 322 −0.49 −1.87 0.89
Duration of diabetes (yrs) 7 10.2 250 10.3 278 1.14 0.28 2.00
Type 1 diabetes 5 15.4 117 14.6 133 1.67 0.82 2.52
Pregestational diabetes 3 6.1 140 6.4 146 0.69 −0.96 2.35
Prepregnancy weight (kg) 4 82.0 154 80.1 190 1.53 −2.21 5.27
Prepregnancy BMI (kg/m2) 3 31.0 140 29.7 139 −0.46 −1.81 0.90
∗
Mean difference: insulin glargine versus NPH insulin.
Table 3: Maternal outcomes of pregnant women using insulin glargine versus NPH among the studies selected for meta-analysis.
Maternal outcomes
Number of
studies
Insulin glargine NPH Mean
difference∗/
odds ratio∗∗
95% confidence limits
Unadjusted
mean/events
Number of
patients
Unadjusted
mean/events
Number of
patients
Lower
limit
Upper
limit
Weight at delivery (kg) 4 93.3 167 92.1 179 −0.82∗ −6.79 5.15
Weight gain (kg) 5 15.1 230 15 265 0.16∗ −1.03 1.35
HbA1c—1st trimester (%) 4 7.67 143 7.65 158 −0.08∗ −0.64 0.49
HbA1c—3rd trimester (%) 6 6.7 252 6.8 286 −0.01∗ −0.07 0.05
Severe hypoglycemia (n) 4 9 155 20 205 0.84∗∗ 0.18 3.79
Pre-eclampsia (n) 8 26 331 40 371 0.55∗∗ 0.23 1.32
Cesarean section (n) 6 199 284 231 324 1.04∗∗ 0.72 1.52
Gestational hypertension (n) 4 9 155 23 205 0.49∗∗ 0.20 1.20
∗
Mean difference: insulin glargine versus NPH insulin; ∗∗Odds ratio: insulin glargine/NPH insulin.
The incidence of preeclampsia was reported in all eight
studies (Figure 2(c)). There was sizable variation between
the studies (I2 = 44%) that could be explained by type of
diabetes. Subanalysis of those studies investigating pregnant
women with type 1 diabetes resolved the heterogeneity
between the studies (I2 = 0%) but did not result in a
significant difference in preeclampsia (OR 0.39 (0.12 to 1.32);
P = 0.13) [35, 38, 40]. One study reported that the incidence
of preeclampsia was higher in pregestational women using
NPH compared to those using insulin glargine (19% versus
0%; P < 0.0001) [39].
The incidence of gestational hypertension was reported
in four studies (Figure 2(d)) [35, 38–40]. While there was
little heterogeneity between the studies (I2 = 1%), in one
study, the use of NPH by women with gestational diabetes
was associated with an increased incidence of gestational
hypertension compared to insulin glargine (18% versus
2.5%; P < 0.0001) [39].
3.4. Neonatal Outcomes. Seven of the eight studies reported
gestational age at delivery [35–39, 41, 42], birth weight [36–
42], and neonatal hypoglycemia [35–41]. When the studies
were analyzed, there were no differences between women
that used glargine or NPH for these outcomes (Table 4,
Figure 3(a)). Within the individual studies, there were also
no differences except for one study which reported that
NPH was associated with a significantly higher incidence of
neonatal hypoglycemia (25% versus 0%; P = 0.01) [37].
Six studies reported the incidence of NICU admissions
[35–37, 39, 41, 42], respiratory distress syndrome [36–41],
and hyperbilirubinemia [35–40]; overall there was no differ-
ence between insulins (Table 4, Figure 3(b)). However, one
study reported that the use of NPH during pregnancy was
associated with an increased incidence of NICU admissions
among the offspring of women with pregestational diabetes
(16% versus 5.5%; P = 0.02) [39], and two studies reported
that NPH was associated with an increased incidence of
hyperbilirubinemia among the offspring of women with
either pregestational or gestational diabetes (31.3% versus
8.3%; P = 0.05) [37] as well as the offspring of gestational
diabetic pregnancies (9% versus 0%; P < 0.01) [39].
Five studies reported the incidence of congenital malfor-
mations [35, 36, 39–41]. While the meta-analysis study result
was not statistically significant (Table 4, Figure 3(c)), one of
the studies associated NPH use with a significant increase in
the incidence of birth defects among the children of women
with gestational diabetes when compared to insulin glargine
use (13% versus 2.5%; P = 0.016) [39].
The incidence of macrosomia [35, 39, 41, 42], LGA
infants [35, 37–39], and 5-minute Apgar scores <7 [37–
39, 42] were each reported in four of the eight studies. There
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(d) Gestational/new-onset hypertension
Figure 2: Meta-analysis results for maternal outcomes.
were no significant differences between the use of glargine
and NPH among the combined or individual studies (Table
4, Figure 3(d)) with the exception of one study which found
that the use of NPH was associated with a significantly
increased incidence of LGA among the infants of women
with pregestational diabetes (50% versus 18.9%; P = 0.04)
[37].
Heterogeneity between the studies assessed for each of
the neonatal outcomes was generally low, with the exception
of the gestational age at delivery (I2 = 71%) and the
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Table 4: Neonatal outcomes of pregnant women using insulin glargine versus NPH among the studies selected for meta-analysis.
Neonatal outcome
Number of
studies
Insulin glargine NPH Mean
difference∗/
odds ratio∗∗
95% confidence limits
Unadjusted
mean/events
Number of
patients
Unadjusted
mean/events
Number of
patients
Lower
limit
Upper
limit
Gestational age at delivery (wks) 7 37.3 289 37 322 0.09∗ −0.43 0.61
Birth weight (g) 7 3463 288 3412 313 12.97∗ −19.18 45.12
NICU admissions (n) 6 94 274 94 307 0.79∗∗ 0.45 1.38
Apgar score—5 minute (<7, n) 4 6 149 4 183 1.36∗∗ 0.26 7.06
Macrosomia (>4000 g, n) 4 37 157 39 198 1.20∗∗ 0.71 2.02
LGA (>90th percentile, n) 4 58 165 75 216 1.05∗∗ 0.68 1.63
Congenital malformations (n) 5 17 237 23 271 0.78∗∗ 0.39 1.59
Respiratory distress syndrome
(n)
6 24 261 15 288 1.62∗∗ 0.82 3.21
Neonatal hypoglycemia (n) 7 58 304 62 346 0.99∗∗ 0.63 1.56
Hyperbilirubinemia (n) 6 58 272 60 314 0.93∗∗ 0.49 1.79
∗
Mean difference: insulin glargine versus NPH insulin; ∗∗Odds ratio: insulin glargine/NPH insulin.
incidence of hyperbilirubinemia (I2 = 44%). While the
heterogeneity of the studies reporting the gestational age at
delivery cannot be explained by the type of diabetes present
during pregnancy, subanalysis of the type 1 pregestational
diabetic women with hyperbilirubinemic children results in
a homogenous population (I2 = 0%), suggesting that the
heterogeneity is due to combining the pregestational and
gestational populations.
4. Summary
In this meta-analysis of eight observational studies, no signif-
icant increased risk associated with the use of insulin glargine
compared with NPH insulin was discerned for any of the
maternal or neonatal outcomes reported. With regard to the
safety of insulin glargine use during pregnancy, in compari-
son toNPH insulin, there was no increased risk to themother
for weight gain, severe hypoglycemia, gestational/new-onset
hypertension, preeclampsia, or cesarean section. While indi-
vidual studies did inconsistently report differences, many of
the individual findings were favorable to insulin glargine.
Glycemic control as measured by first and third trimester
HbA1c was not different between the pregnant women using
insulin glargine and those using NPH insulin.
5. Discussion
Few studies were identified which have addressed the safety
of insulin glargine versus NPH use during pregnancy, and
many of those identified were conducted with small study
populations. The current meta-analysis of these published
studies found no significant differences in maternal or fetal
health outcomes or complications associated with the use of
insulin glargine in comparison to NPH.
The neonatal outcomes of this study are in accordance
with those reported in a recent meta-analysis of the neonatal
safety of insulin glargine use during pregnancy [43]. While
the eight studies identified in this meta-analysis are the same
as those identified and analyzed in the previous study,
it focused primarily on neonatal outcomes and no meta-
analyses were performed on any of the maternal outcomes
reported in the studies. Similar to the current study, there
were no significant differences between the use of either
insulin glargine or NPH with regard to adverse neonatal
outcomes. Divergent data extraction methods resulted in
the selection of slightly different study subject numbers or
adverse event numbers for analysis. For example, among the
304 insulin glargine patients and 346 NPH patients with
neonatal hypoglycemia data, the Pollex study identified 57
women treated with insulin glargine and 66 women treated
with NPH whose offspring were hypoglycemic. In contrast,
the current study identified 58 women treated with insulin
glargine and 62 women treated with NPH. Meta-analysis of
the neonatal hypoglycemia outcomes resulted in an odds
ratios of 0.94 (0.64–1.39) for the Pollex study and 0.99
(0.63–1.56) for the current study; both differences were
not statistically significant. Different statistical algorithms
may also account for the variation between the results of
the two studies. Analysis of the prevalence of respiratory
distress syndrome utilized the same raw data but resulted
in slightly lower but statistically nonsignificant odds ratios
in the Pollex study (1.53 (0.82 to 2.85) versus 1.62 (0.82 to
3.21)). While the results are not identical, the corresponding
neonatal outcomes in the current study are comparable with
the previous report.
The present analysis demonstrated similarly equivalent
findings between treatment with insulin glargine and NPH
insulin for maternal outcomes, which were not addressed
in the Pollex study. One aspect of the maternal findings of
the present analysis requires further comment; women using
insulin glargine had longer duration of diabetes than those
using NPH insulin. Although the weighted mean difference
in the duration of diabetes was significant, there was
substantial heterogeneity between the studies. Subanalysis
of the studies based on type of diabetes suggests that
the heterogeneity was due to the combination of patients
with type 1 and type 2 diabetes into a single cohort. The
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Figure 3: Meta-analysis results for neonatal outcomes.
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implications of this finding are uncertain. It is possible that
the longer duration of type 1 diabetes among women using
insulin glargine was due to women switching to the newer
insulin glargine from established insulin regimens in order
to achieve better glycemic control than that provided by their
prior insulin therapy.
The finding in this analysis that maternal and fetal
complications did not differ between women using insulin
glargine and those using NPH insulin is consistent with
recent findings regarding the metabolism and actions of
insulin glargine. Much of the concern about insulin glargine
stemmed from in vitro experiments exposing human osteo-
sarcoma cells (Saos/B10) to insulin glargine which revealed
a 6.5-fold higher affinity for the IGF-1 receptor and an 8-
fold greater mitogenic action in comparison to insulin [31].
However, experiments using other cell lines and, in particu-
lar, human skeletal muscle cells, coronary artery cells, blood
vessel endothelium cells, normal epithelial breast, and cancer
cell lines have suggested a mitogenic and metabolic potency
of insulin glargine similar to that of human insulin [30,
44–46]. Moreover, recent in vivo studies have shown that
insulin glargine is converted into two metabolites which are
metabolically active and may account for most of the action
of insulin glargine, but which have an affinity for the IFG-
1 receptor that is comparable to that of human insulin
[47]. These results suggest that insulin glargine is unlikely to
adversely affect fetal development [48, 49].
This meta-analysis has a number of limitations. It was
based on data from observational studies and consequently,
the participants were not randomized and there were
insufficient data in the papers to allow statistical adjustment
of the combined comparisons. While there was no significant
difference in all but one of the baseline characteristics, the
confidence intervals were often wide and not all studies
reported each baseline characteristic. For example, only three
of the eight studies utilized in the meta-analysis reported the
BMI of study participants. Of those studies, the mean BMI
of the women in two of the studies indicate that a significant
number of them are obese. Studies have found that, similar
to diabetes, obesity is associated with an increased risk of the
same adverse outcomes including gestational hypertension,
preeclampsia, cesarean section, stillbirth, congenital malfor-
mations, and macrosomia [50, 51]. In addition, there may
be confounding due to unmeasured characteristics such as
socioeconomic status and race. There was little racial/ethnic
background information available for the participants of
the study. This could be of importance as certain ethnic
backgrounds may predispose subjects to certain adverse
outcomes, confounding the results. A recent literature review
found that ninety-three of the included 106 studies reported
at least one significant association between socioeconomic
measures and birth outcomes among the overall study
population or within a racial or ethnic subgroup [52].
Maternal complications are also impacted by socioeconomic
status and race; several studies have found that low socioeco-
nomic status and nonwhite races are substantial risk factors
for preeclampsia [53–55]. All but one of the studies was
retrospective in design; data may not have been available
for collection, limiting the scope of the study. Retrospective
analysis also allowed for the selection of patients that had
continuous insulin glargine or NPH treatment throughout
pregnancy, precluding study of the impact of switching basal
insulin use during pregnancy; only one study reported that
a single patient was switched from NPH to insulin glargine
during pregnancy [40]. The only observational prospective
study included in the meta-analysis did not report any
changes in basal insulin use [39]. Another limitation to
the meta-analysis was the study population available for
investigation. During the identification of studies to be
included in the meta-analysis, few studies contained a
sufficient number of patients to be included in the analysis;
many of the excluded studies reported data for fewer than
fifteen patients in total and often had only a single treatment
arm. Among the eight studies included in the meta-analysis,
only four contained data for more than one hundred patients
among the combined treatment arms. The number of
participants within each treatment arm was as low as fifteen
patients per study, hindering statistical comparison between
groups.While there were no statistically significant outcomes
to report in this meta-analysis, the combined analysis of
the individual study populations was underpowered due to
the limited sample sizes. Consequently, the risk of rarer
complications of pregnancy associated with diabetes such as
worsening of preexisting maternal retinopathy or nephropa-
thy, or occurrence of polyhydramnios and fetal mortality
associated with diabetic ketoacidosis, cannot be assessed. An
additional limitation to the study was the grouping of type
1 and type 2 diabetes patients into a single pregestational
diabetes cohort. Only one of the studies included in the
meta-analysis reported findings for all outcomes separately
for each type of pregestational diabetes [42]. Moreover, only
a subset of the studies compared outcomes between patients
with pregestational and gestational diabetes [37, 39, 41].
Finally, exposure to insulin glargine or NPH during the 1st
trimester was limited to the five studies that focused on
pregestational diabetes.
6. Conclusions
The results of this meta-analysis did not show differences in
maternal or neonatal outcomes in women with diabetes who
were treated with glargine compared to NPH. Because the
quantitative estimates of difference for individual measures
had large uncertainties, accumulation of more data is
warranted, preferably by conducting randomized controlled
trials or prospective observational studies in which partici-
pants are followed for longer periods of time.
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